logo
ResearchBunny Logo
Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML

Medicine and Health

Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML

D. Nixdorf, M. Sponheimer, et al.

Discover the innovative 4dCAR T-cell platform for AML immunotherapy developed by D. Nixdorf and colleagues. This groundbreaking approach tackles the critical challenges of target antigen heterogeneity and T-cell dysfunction, demonstrating promise through its effective cytotoxicity against AML. Experience a new frontier in cancer treatment!

00:00
00:00
Playback language: English
Abstract
Current AML treatments have limitations, with relapse being common. This study presents a novel Fab-based adapter CAR (4dCAR T-cell) platform for AML immunotherapy, addressing challenges in target antigen heterogeneity, safety, and T-cell dysfunction. In vitro and in vivo experiments demonstrated AML-specific cytotoxicity using anti-CD33, anti-CD123, and anti-CLL1 adapter molecules. Sequential application of adapter molecules with different specificities proved feasible. The platform also mitigates T-cell exhaustion through treatment-free intervals.
Publisher
Leukemia
Published On
Apr 27, 2023
Authors
D. Nixdorf, M. Sponheimer, D. Berghammer, F. Engert, U. Bader, N. Philipp, M. Kazerani, T. Straub, L. Rohrbacher, L. Wange, S. Dapa, D. Atar, C. M. Seitz, K. Brandstetter, A. Linder, M. von Bergvelt, H. Leonhardt, J. Mittelstädt, A. Kaiser, V. Bücklein, M. Sukbwele
Tags
AML
immunotherapy
4dCAR T-cell
cytotoxicity
adapter molecules
T-cell exhaustion
target antigen

Related Publications

Explore these studies to deepen your understanding of the subject.

Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy
Medicine and Health

Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy

Y. Li, Y. Cong, et al.

Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL
Medicine and Health

Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL

J. Zhang, Y. Hu, et al.

Locoregional delivery of IL-13Rx2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial
Medicine and Health

Locoregional delivery of IL-13Rx2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial

C. E. Brown, J. C. Hibbard, et al.

speedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing
Medicine and Health

speedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing

R. Castellanos-rueda, R. B. D. Roberto, et al.

Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny